Acute hepatic failure in children. by Riely, C. A.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 57 (1984), 161-184
Acute Hepatic Failure in Children
CAROLINE A. RIELY, M.D.
Associate Professor ofMedicine and Pediatrics, Yale University School of
Medicine, New Haven, Connecticut
Received June 27, 1983
Many diseases may present as acute hepatic failure in the pediatric age group, including viral
hepatitis A and B, adverse drug reactions, both toxic and "hepatitic," and inherited metabolic
disorders such as tyrosinemia, a, antitrypsin deficiency, and Wilson's disease. Management is
primarily supportive, with care taken to anticipate the known complications ofhepatic failure.
Few "curative" therapies are known, although attempts at stimulating hepatic regeneration
may be helpful.
Acute hepatic failure is a rare but devastating event with a mortality rate of 80
percent or higher in adults [1-4]. For children, survival may be somewhat higher as
the liver, particularly the young liver, has remarkable regenerative powers. Full
recovery to normal hepatic structure and function is possible, even after massive in-
jury. Because of this potential for full recovery, all patients with acute hepatic
failure require intensive care. Only the most meticulous, most intensive support is
rewarded, albeit far from invariably, with salvage ofpatients from this catastrophic
syndrome.
Acute hepatic failure is a non-specific term, implying abrupt cessation of hepatic
function of any etiology (Table 1). First, it is acute, with signs and symptoms
fulminating over a very short period, usually less than two weeks and often only
hours. Chronic liver diseases which may terminate in an acute fashion are excluded
from this diagnostic category. Some liver diseases may progress in the absence of
overt signs or symptoms to an acute termination, however, so that the differential
diagnosis of acute hepatic failure should include some chronic liver diseases also,
Wilson's disease being a prime example. Not included within this diagnosis (or
within this review) areclearlychronic forms ofliver disease, such as biliaryatresia or
chronic hepatitis.
The second requirement for this diagnosis is hepatic failure, the inability of the
liver to maintain its major functions (Table 1). Hepatic coma with hyperam-
monemia is necessary for the diagnosis of acute hepatic failure, as is coagulopathy,
with prolongations of the prothrombin and partial thromboplastin times. In acute
hepatic failure, the prolonged prothrombin time is not responsive to parenteral
Vitamin K; correction of the prothrombin time after Vitamin K administration im-
plies long-standing malabsorption ofthis fat-soluble vitamin and demonstrates nor-
mal hepatic function, once absorption has been bypassed.
Almost invariably, other tests of hepatic function are also abnormal in acute
hepatic failure (Table 2). The albumin level is often below 4 g/dl, despite the long
half-life of this protein. The level of cholesterol, another product of hepatic syn-
thesis, is also usually low, often below 100 mg/dl. In addition to these defects of
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TABLE I
Criteria for thle Diagnosis of Acute Hepatic Failure
1. Acute: Rapid deterioration from health to coma over a short time course(usually less thani two weeks).
2. Hepatic failure:
a. Coma with hyperammonemia
b. Coagulopathy: prolonged prothrombin (PT) and partial thromboplastiin times (PTT)
c. Other hepatic dysfunctions: decreased serum levels of albumin and clholesterol, elevationis in
both direct and indirect reacting bilirubin
d. Signs of acute hepatic necrosis: elevations in serum transaminiases (commoni but niot
invariable)
hepatic synthetic function, the excretory function of the liver is also impaired, with
elevations in the serum bilirubin (both direct and indirect fractions). As a result,
jaundice is common in acute hepatic failure, although it may take several days to
become clinically evident. In very fulminant cases, the patient may lapse into coma
before becoming obviously jaundiced. Nevertheless, the diagnosis of acute hepatic
failure is difficult to support without an elevation, although it may be mild, in the
bilirubin.
Conventional "liver function tests" usually include the serum transaminases
(SGOT-AST and SGPT-ALT) which are often elevated in acute hepatic failure,
although such elevations are not mandatory to confirm the diagnosis. The levels
may be very high-for example, up to 6,000-10,000 units in acute viral hepatitis.
TABLE 2
Interpretation of Common Tests of Hepatic Function
Normal Usual Level in Acute
Name Range Hepatic Failure Interpretation
Ammonia < 150 ug/dl t Failure of appropriate hepatic
metabolism
Prothrombin Within 2 seconds 1, >3 seconds prolonged Inadequate hepatic production
time of control of factors
Partial Within 5 seconds t, >5 seconds prolonged Inadequate hepatic production
thromboplastin of control of factors
time
Albumin 3.7-4.8 g/dl 1, <3.4 g/dl Inadequate hepatic production
and hemodilution
Cholesterol 150-230 mg/dl l, < 150 mg/dl Failure of hepatic production
and hemodilution
Bilirubin Mixed defect in hepatocyte
Total < 1.5 mg/dl t,>2.0 mg/dl uptake and excretion
Direct <0.30 mg/dl t,> 1.0 mg/dl
SGOT 15-35 units I, > 500 units Acutenecrosis(may arisefrom
muscle or heart as well)
SGPT <32 units 1, >500 units Acute necrosis (somewhat
more specific for liver)
Alkaline 10-20 units/L Modestly t or normal Membrane enzyme, elevations
phosphatase more common in chronic
cholestasis than in acute
hepatic necrosis
Also elevated during rapid
bone growth
5'nucleotidase < 10 Iu Modestly t or normal Hepatic fraction of alkaline
phosphataseACUTE HEPATIC FAILURE IN CHILDREN
TABLE 3
Hyperammonemia Without Hepatic Failure in Children: Major Causes [51
1. Primary urea cycle defects
Carbamyl phosphate synthetase I deficiency
Ornithine transcarbamylase deficiency
Arginosuccinate synthetase deficiency
Argionosuccinase deficiency
Arginase deficiency
2. Organic acidemias [6]
Propionyl CoA carboxylase deficiency [7]
Methylmalonyl-CoA mutase deficiency [8]
3. Carnitine deficiency [9]
4. HHH Syndrome (hyperornithinemia, hyperammonemia, homocitrullinuria) [101
5. Familial lysinuric protein intolerance [11]
Such elevations reflect acute necrosis but give no hint as to hepatic function or
prognosis. Chronic hepatic failure may be associated with normal transaminase
values, whereas patients with markedly abnormal transaminases may have intact
hepatic function.
Other "liver function tests," such as alkaline phosphatase, may be abnormal, but
less impressively so. It is helpful to monitor enzymes more specific to the liver, for
example 5'nucleotidase, as the less specific alkaline phosphatase is usually elevated
in children, reflecting bone growth.
In children, the differential diagnosis ofacute hepatic coma must include a host of
enzyme defects which may be associated with hyperammonemia (Table 3). The most
commonly encountered of these is a defect in the urea cycle enzyme ornithine
transcarbamylase. These hyperammonemic states all share an important feature
which differentiates them from acute hepatic failure: hepatic function is well-
preserved, as a rule. Such patients may show transient elevations of transaminase,
but have normal coagulation tests, bilirubin, and albumin values. These syndromes
ofisolated hyperammonemia will not be further discussed herein. Also not included
in the discussion which follows is the most common hyperammonemic state seen in
children, namely Reye's syndrome [12].
Acute hepatic failure is a devastating event with high mortality. Although its
management is only supportive for the most part, it is crucial to try to identify the
cause ofthe hepatic failure. Specific cures or antidotes are rare in this disease entity,
but they do exist and must be proffered where appropriate. Not uncommonly, the
"cause" of the hepatic failure is a drug being administered by well-meaning physi-
cians in all good conscience; in these instances, identifying the causative agent, and
removing it, is crucial if recovery is to take place.
DIAGNOSIS OF ACUTE HEPATIC FAILURE
Diagnostic Tools
Determining the cause of acute hepatic failure requires the use of both old and
new diagnostic tools. Crucial to arriving at the correct diagnosis is a good history,
which often must be obtained from the family, as the patient is in a coma. A history
of exposure, either to epidemic hepatitis, blood transfusion, drugs, or toxins is
helpful. In children, the history of growth and development, along with a growth
chart, may indicate pre-existing disease. A family history of infantile deaths or of
members with cirrhosis would suggest genetic disease. Physical examination should
163CAROLINE A. RIELY
be directed toward detecting signs of chronic liver disease, especially palmar
erythema, spider angiomata, and prominent venous pattern over the chest and ab-
domen. Cutaneous signs of allergic reactions, such as a drug exanthem, or of viral
infection are very useful. The liver size is important and both the total span to per-
cussion and the span to palpation below the costal margin should be measured and
recorded on admission. Hepatomegaly should suggest genetic disease, whereas a
normal-sized liver which progressively shrinks suggests hepatitis with an ominous
prognosis (Fig. 1). Splenomegaly is usually not present in acute hepatic failure and,
if the spleen is found to be enlarged on admission, chronic forms of liver damage
should be considered.
Laboratory tests are helpful in confirming the etiology of acute hepatic failure,
but should not supersede experienced clinical input. A differential white count with
a pronounced eosinophilia suggests an allergic reaction, and can be very helpful if
present. In hypersensitivity, the absence of eosinophilia is the rule, however, and in
no way excludes this diagnosis. Standard "liver function tests" (bilirubin, SGOT) are
surprisingly non-specific in acute hepatic failure. A very high SGOT (i.e., > 5,000
units) suggests massive necrosis as in viral or drug hepatitis, but both may occur
without large SGOT elevations or the peak elevation may be missed. Confirmation
ofthe etiology ofviral hepatitis depends on serologic testing (Table4). This field has
seen an explosion of knowledge in the last 15 years, and new serologic tests for new
viral hepatitides are reported frequently [16]. Several such markers have yet to be
reproduced. Despite this, the promise of further elucidation of the viral hepatitides
and their serologic markers is great. The laboratory can also be helpful in confirm-
ing drug and toxic hepatitis. All patients admitted with acute hepatic failure should
have urine and blood samples taken on admission for possible toxic screening. Ex-
cept for acetaminophen, however, no correlation has been established between
blood levels of drug and degree of hepatic injury.
The percutaneous liver biopsy technique introduced in the 1950s provided a quan-
_~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~...F..
FIG. 1. Radiographs of the abdomen
in a patient with fulminant hepatitis;
note the small shrunken liver.
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TABLE 4
Hepatitis Serologies [13,14]
Agent Marker Initerpretation
Hepatitis B HBsAg
anti-HBsAg
anti-HBcAg
HBeAg
Hepatitis A
(HA) [15]
Non-A, nion-B
hepatitis
(HNANB) [16]
EBV [17]
CMV [18]
ainti-HBeAg
anti-HA
IgG
1gM
Several preliminary
reports
Monospot
(Orth Diagnostics)
Anti-viral capsid
antigenl, IgM anid
IgG
Anti-early antigen
Anti-EB nuclear
antigenl
CMV antibody
IgM and IgG
Excess viral surface protein
Anitibody to surface protein
Anitibody to core anitigeni
A third anitigeni associated with HB,
onily presenit conicomitanit with
HBsAg, usually early ill disease,
correlates witlh higlh HBsAg anid
with infectivity
Antibody to HBe
Conifirms exposure (may be distanit)
Conifirms recent inifection
Correlates with cliniical hepatitis whiic
has been showni serologically to be
nieither A or B; probably multiple
viruses
Screeninig test-usually + early in
inifectioni, false + occur
High titer in acute phase, IgG persists
for life
Occurs early, tlhen fades
Occurs in convalescenit phase, persists
for life
Widely used but iniadequately senisitive;
maniy false -, small rises in titer
are inoni-specific
tum jump in diagnostic accuracy of liver diseases. This technique is suitable for use
in infants and children as well as adults. Its limitations are real, however. In our in-
stitution, we do not perform this procedure in the face of coagulopathy (prothrom-
bine time > 3 seconds prolonged, platelet count < 60,000, template bleeding
time > 9 minutes). Occasionally these problems can be circumvented by infusions
of fresh frozen plasma or ofplatelets, but even a corrected coagulopathy represents
a relative contraindication to biopsy. Other limitations of liver biopsy should be
remembered: as a rule the findings in viral hepatitis (most kinds) and in drug-
induced hepatitis (hypersensitivity) are indistinguishable. Liver biopsy cannot
predictably distinguish one type of hepatitis from another.
As a result of these limitations, liver biopsy is rarely performed in patients with
acute hepatic failure. Our practice has been to limit the use of this procedure to pa-
tients without coagulopathy whose history and course are atypical for viral or drug
hepatitis and whose disease evades diagnosis by less invasive means.
Viral Hepatitis [13,14]
Hepatitis B The identification of this viral agent resulted in a Nobel Prize for
Baruch Blumberg in 1976. Trials with a vaccine have been very successful [19] and
conquering this disease, the most common cause of liver disease worldwide, would
surely rank as one of the premier medical achievements of the second half of the
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twentieth century. Hepatitis B is probably the single most common cause of acute
hepatic failure. This illness can occur in several other ways as well, including the
asymptomatic carrier state, chronic active hepatitis, "cryptogenic" cirrhosis, and in
association with hepatocellular carcinoma. The disease is common, with incidences
in the general population ranging from about0.5 percent in the U.S. to 20 percent or
more in parts ofthe Far East andAfrica. The most common route oftransmission is
vertical transmission from mother to infant, presumably occurring at birth [20]. In-
fants infected in this way are usually asymptomatic, although some will have fulmi-
nant hepatitis. Presumably, it is this route ofspread which is responsible for the high
incidence ofthe hepatitis B surface antigen carrier state in somepopulations. Studies
have shown that vertical transmission is more likely to occur if the mother is also
positive for hepatitis Be antigen (Table 4 and figs 2), an antigen associated with
hepatitis B whose presence correlates with high titer of hepatitis B surface antigen,
high levels of DNA polymerase, and also with greater infectivity. When hepatitis B
is transmitted vertically, the infant shows conversion to hepatitis B antigen positivity
usually in the third to fourth month, suggesting that the infection was acquired
traversing the birth canal or in the immediate peripartum period. It seems unlikely
that this virus crosses the placenta, as cord blood is almost invariably negative.
Therefore, most cases of infantile hepatitis B occur in or after the third month of
life, although fulminant hepatitis B has been observed within one or two months
after birth.
In addition to vertical transmission, this virus is also transmitted through blood
products. With all volunteer donors and with screening for HBsAg, the incidence of
post-transfusion hepatitis B has fallen dramatically but persists at a real but much
reduced rate. As the infection is cleared from the body, hepatitis B surface antigen
disappears before antibody to hepatitis B surface antigen can be detected (Fig. 2). In
this so-called window period, the only marker in the blood indicating persistent viral
infection is the IgM antibody to hepatitis B core antigen. Until all transfused blood
is routinely screened for this marker, a small rate ofpost-transfusion hepatitis B will
persist.
Finally, hepatitis B occurs commonly as sporadic hepatitis. Infection can occur
from ingesting a large viral load orally, despite the fact that the gastric milieu kills
the virus in small doses. A common route of transmission is intimate prolonged
physical contact with an infected person. Sexual transmission is the usual route and
this infection is very prevalent in themale homosexual population. The contact must
be intimate, however, as studies in families have shown an increased rate of
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FIG. 2. Serologic events in the course oftypical hepatitis B. Compare with Table 4 (from [13]. Repro-
duced with permission ofMasson Publishing USA, Inc.).
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transmission only between sexual partners and not from parent to child. Spread is
also common in residential treatment centers for the mentally retarded, where
behavioral problems (biting, sexual promiscuity) are frequent. Recent reports have
suggested local spread within the normal classroom setting, but have yet to be con-
firmed [21].
Once a case of hepatitis B has been confirmed, multiple questions about pro-
phylaxis and isolation arise. As a rule, only sexual contacts of the affected patient
need receive immunoprophylaxis. It is difficult to be dogmatic about this stance and
some physicians may advise prophylaxis for persons in close contact (kissing, shar-
ing bottles) with the child. For the patient who is hospitalized, the staff should
realize that transmission only occurs if blood or other fluids (tears, semen, saliva)
from the infected patient penetrate the skin or mucous membranes of the exposed
person. The most common route, therefore, is by puncturing the skin with a needle
from the patient. Strict needle precautions are in order; there should be a needle-
destroying kit at the bedside, and it should be disposed of properly. Blood spills
represent a real hazard (this includes menstrual flow), and should be cleaned up with
hypochlorite solution (Clorox diluted as a 1:10 solution in water) which kills the
virus. Other than this, the patient is not highly infectious and the virus is not
transmitted by talking or touching. Despite this, many hospitals persist in requiring
gown and glove precautions.
Once the decision to give prophylaxis has been made (and this should be decided
as soon as possible after exposure, i.e., within 48 hours), the exposed individual
should be checked for both hepatitis B surface antigen and antibody to hepatitis B
surface antigen. If either is present, no prophylaxis is needed, as viral infection is or
has been present. If neither is present, the exposed person is given 0.06 ml/kg of
hyperimmune hepatitis B globulin with a repeated dose in one month. The globulin
is very expensive. The best prophylaxis for doctors and nurses at risk is informed
care of the patient, with respect to needles and blood. If the exposed individual will
be chronically exposed (i.e., health care worker, spouse of a chronic carrier), then he
or she should also be actively immunized with vaccine.
The clinical hallmarks of hepatitis B can be very helpful in confirming this infec-
tion as the cause of acute hepatic failure. Early in the course of the infection (before
any symptoms of hepatitis), the patient may experience a rash which may be either
typical hives or the acrodermatitis described by Gianotti and Crosti [22]. These
rashes are usually evanescent and, unless they are recognized at the time as the pro-
drome of acute hepatitis B, are only helpful in retrospect. The patient who is to
develop fulminant hepatitis B progresses from well to critically ill within five to ten
days, as a rule [23]. The symptoms are those of classical hepatitis: anorexia, nausea,
vomiting, and jaundice. Hepatic coma may begin as unusual irritability and per-
sonality changes, before the onset of lethargy and frank coma. Initially the liver may
be modestly enlarged but it shrinks rapidly in fulminant hepatitis (Fig. 1). Early in
the course, the SGOT is usually very high (i.e., > 1,000) but may fall rapidly. The
findings on liver biopsy are not specific (Fig. 3).
As a rule, fulminant hepatitis B does not occur in chronic carriers or in patients
with chronic liver disease secondary to this virus. One exception to this rule is
chronic carriers who have been immunosuppressed (for example, a multiply
transfused leukemic). Several reports have documented fulminant hepatitis B in this
setting when immunosuppression was discontinued [24].
Serologic testing is the key to confirming this diagnosis (Table 4). All patients with
acute hepatic failure should be checked for HBsAg. If it is positive, then, almost in-
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variably, the patient has fulminant hepatitis B. In that instance, the family members
should be checked for HBsAg and anti-HBs. If the mother of an affected neonate is
positive for HBsAg, testing for e antigen may be helpful in assessing her infectivity.
In the HBsAg-positive patient with fulminant hepatitis, testing for HBeAg, anti-
HBe, and anti-HBc is superfluous but may give some indication of the duration of
the infection and its prognosis.
Hepatitis A This infection is a less frequent but occasional cause of acute
hepatic failure [15]. Most cases of hepatitis A are subclinical. It is very common,
particularly in underdeveloped countries but also in the United States, where, by the
age of 50, 70 percent of the population show serologic evidence for past infection.
Many have no past history compatible with acute hepatitis. The incidence ofpositive
markers for this infection is age-related and it is uncommon in children.
In this infection, viremia is very short-lived, usually less than ten days to two
weeks, and the viremia has cleared by the time that the symptoms of hepatitis are
recognized, or shortly thereafter. There is no chronic carrier state for hepatitis A.
Knowledge of these facts will allow the clinician to accurately predict the
epidemiology of this virus. Hepatitis A does not occur as post-transfusion hepatitis,
because of the transience of viremia and the absence of the chronic carrier state. It
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occurs in common-source water- and food-borne epidemics or by fecal-oral
transmission from an infected human. Within one to two weeks of the onset of
symptoms of hepatitis A, virus is no longer being shed in the stool and the infected
patient is no longer contagious. Immunoprophylaxis, as 0.02 ml/kg of regular
gamma globulin, is indicated for all individuals who are not already immune who
share exposure with the affected patient-i.e., family members, contacts in a resi-
dential situation. Failure to provide this immunoprophylaxis is hardly catastrophic,
however, as the infection is usually subclinical and as most of us will encounter it
eventually. The hospitalized patient with hepatitis A should be maintained on stool
and syringe precautions but does not represent a very great threat, as viremia ceases
promptly.
Clinically, fulminant hepatitis A is confirmed serologically, using testing for anti-
hepatitis A. The antibody should be classified as to immunoglobulin class: IgG an-
tibody indicates distant infection and should not be used as evidence for acute
hepatitis A. In acute disease, the antibody is of theIgM class. This titer falls with
time after the infection as the IgG titers rises. As viremia is so evanescent, testing for
hepatitis A antigen is neither practical nor clinically available.
Non-A, Non-B Hepatitis This catch-all phrase is use to include any hepatitis
which cannot be confirmed to be either A or B. The term is generally restricted to
primarily hepatic disorders and is not used to describe systemic diseases which can
have hepatic involvement, such as mononucleosis. Confirmed markers for specific
viral infections within this group are not yet available. When they become so, they
will probably be identified as hepatitis C, hepatitis D,
and forth.
Until such time,
the designation of non-A, non-B hepatitis remains a wastebasket term.
Within this designation, however, there exists at least one well-defined clinical
syndrome, probably resulting from infection with a single virus [25]. This form of
non-A, non-B hepatitis is now the most common post-transfusion hepatitis [26].
Usually the disease has its onset approximately three months after the transfusion, is
subclinical or very mild, and results in a chronic disease with transaminase values
rising and falling within a range of normal to 500 units over two- to five-year period.
The biopsy during
this period may show chronic active hepatitis and cirrhosis may
result, although in most patients the disease eventually resolves. This disease may
also present as fulminant hepatitis, and is probably the second most common cause
of fulminant viral hepatitis, in children as well as adults. This disease is a "serum"
hepatitis and, presumably, when markers become available, it will be shown to have
epidemiology more similar to that of hepatits B than of hepatitis A.
Clinically, fulminant non-A, non-B hepatitis is indistinguishable from other
forms of fulminant hepatitis. There is no serologic proof for this infection and this
term should be used only as a diagnosis of exclusion, after all other serologies fail to
reveal the cause and after ingestion of drugs or toxins has been ruled out.
Infectious Mononucleosis Very rarely, the liver may become severely involved
during the course of typical "mononucleosis" [17]. Death in hepatic coma has been
reported in this entity [27]. The diagnosis should be suggested by a prodrome com-
patible with mononucleosis, e.g., fever, sore throat, generalized tender lymph-
adenopathy. This syndrome may be caused by either Epstein-Barr virus (EBV) or by
cytomegalovirus (CMV) [18].
Serologic tests may be helpful (Table 4), particularly in establishing acute infec-
tion with EBV. Serologic testing for CMV is available, but in most laboratories is
mono-valent, and thereby too specific to be generally useful. In addition, this titer
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may rise in the absence of demonstrable disease caused by CMV. Both EBV and
CMV can be cultured from infected persons. Recovery ofvirus depends upon cultur-
ing fresh specimens (for example, freshly passed urine) and use ofthe correct cultur-
ing technique. Cultures may take weeks to turn positive [17,18].
Congenital Hepatitis Several viruses can infect the neonate in utero or in the
perinatal period and cause so-called congenital hepatitis [28,29]. Rarely, this type of
hepatitis may assume a rapid progression and may result in acute hepatic failure
within the first six weeks oflife. Often these patients will have other signs suggesting
systemic or congenital viral infection: thrombocytopenia with "blueberry muffin"
rash, congenital heart disease, cataracts or retinal disease, deafness, or vesicular
eruption on the skin or mucous membrane. In all such patients (invariably
neonates), serologic proof of the suspected agent should be sought in both infant
and mother. Testing for specific immunoglobulin classes of antibody (e.g., IgM,
IgG) should be used. Acute infection in the infant cannot be presumed in the
absence of IgM antibody, which, unlike IgG antibodies, does not cross the placenta
and cannot be of maternal origin. In addition, several of these viruses can be suc-
cessfully cultured from affected patients.
Adverse Drug Reactions
Drugs and chemicals are a common cause of acute hepatic failure [30,31]. The va-
riety of offending agents and the diversity ofpossible reactions presents a bewilder-
ing picture to the clinician. The following working hypothesis (Table 5) can serve as
a framework for better understanding of these reactions, even though some do not
readily fit into the model. This schema should be taken only as a guide, as in most
cases the exact pathogenesis of adverse drug reactions is still unknown.
Classification
Toxins Drugs and chemicals which predictablyproduce atypical adverse reac-
tion in both animals and man may be considered toxins. Luckily, few ofthese reach
commercial availability in this era of government regulation and testing in animals.
These agents will produce an adverse response in all individuals receiving the thresh-
old dose or more. The lesion begins at a predictable (usually short) time after ad-
ministration and results in a typical pathologic appearance in the biopsy of either
man or animal. Because of this predictability, for at least one toxin (acetaminophen),
TABLE 5
A Method for Classifying Adverse Hepatic Reactions
to Drugs and Chemicals [30]
Toxins Sensitizers
Predictable Idiosyncratic
Dose-related Not dose-related
Occurs in all exposed Occurs only in a fraction of
exposed persons
Reproducible in animals Not identically reproducible in
animals
Short time of onset Onset is variable
Consistent histopathology Histopathology is variable
Examples:
Acetaminophen, CCl4 Dilantin, INH, Halothane
Akee fruit
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the mechanism of toxicity has been clearly elucidated and an antidote is known. The
agents are poisons to all, given a sufficient dose.
Sensitizers Drugs in common clinical use may rarely cause adverse hepatic
reactions. These agents do not cause similar reactions in animals and, thus, are able
to reach the public. The reactions are idiosyncratic, occur at a variable (often pro-
longed) interval after initiation of therapy, result in a variety of histo-pathologic
responses, and occur in only a small minority of the exposed population, without
regard to dose. Unlike the response to toxins, these reactions may be accompanied
by systemic signs of hypersensitivity, including fever, rash, and eosinophilia.
Toxins-Examples
Acetaminophen This readily available drug is a common vehicle for suicides
in England and overdoses, either intentional or accidental, are becoming more fre-
quent in this country. Acute ingestion of an overdose results in acute hepatic failure.
Chronic ingestion of smaller (perhaps even therapeutic) doses can result in chronic
hepatitis-at least in adults. Immediately after the ingestion the patient is often
remarkably well, although some demonstrate vomiting and shock. For the first one
to two days, the liver function tests remain normal. By the third day, hepatic
necrosis begins, probably initiated by depletion of hepatic glutathione stores by the
overwhelming dose of the drug, leaving no glutathione to bind to a minor product of
metabolism, which in turn binds covalently with the liver, causing necrosis [32].
Once initiated, this necrotic process progresses to massive hepatic necrosis, hepatic
coma, and death. The pathologic picture is a predictable one of confluent central
hemorrhagic necrosis (Fig. 3).
Great gains have been made in the management of this entity and progression to
death is now the exception rather than the rule, provided that the ingestion is
recognized early and appropriate therapy initiated (see below) [33]. Appropriate
therapy should blunt or ablate the necrotic reaction. A single ingestion, regardless of
severity, results in no hepatic sequelae, providing the patient survives. If detected
early, the average patient with acetaminophen overdose does not require intensive
care. Nevertheless, the clinician should be reminded that the hepatic necrosis begins
late, three days after ingestion, and should monitor for this.
Other typical hepatic toxins include carbon tetrachloride [34], and amanita
phalloides [35], the toxin in the amanita species of mushroom, the "angel of death."
Both produce microvesicular fatty infiltration of the liver, predominantly in the cen-
tral zones. Again, like acetaminophen, the hepatic necrosis peaks at two to three
days after ingestion. Death occurs if the dose is large enough.
Many other true toxins for the liver exist. One of particular interest in pediatrics is
that in unripe akee fruit, the national fruit of Jamaica. When this unripe fruit is con-
sumed, the patient develops vomiting and hypoglycemia, lapses into coma, and
dies-so-called Jamaica vomiting sickness. The illness is similar to Reye's syndrome
in many respects, including the presence of microvesicular fat in hepatocytes. The
toxic compound present in the fruit is an unusual amino acid, hypoglycin, which in-
terferes with long-chain fatty acid metabolism [36]. This illness may be a model for
the coma seen in the organic acidemias.
Sensitizers-Examples Several drugs in widespread clinical use can cause fulmi-
nant hepatitis indistinguishable from viral hepatitis. A typical example is di-
phenylhydantoin [37]. Usually, the hepatitis has its onset within three months of ini-
tiating therapy, but the onset may be variable. Many patients will have hepatitis as a
part of a generalized "allergic" reaction, including fever, eosinophilia, skin rash, and
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lymphadenopathy. The hepatitis may occur in isolation, however. The time course
of this illness is fulminant with symptoms typical of hepatitis followed rapidly by
coma. The transaminase values may be very high, as in viral hepatitis. The liver
biopsy may show eosinophils prominent in the infiltrate, but this is not an invariable
finding and the biopsy picture is usually indistinguishable from acute viral hepatitis.
If the patient survives, there are no hepatic sequelae as a rule. The single most im-
portant step in therapy is to stop the drug, although the hepatic necrosis often pro-
gresses despite discontinuing the offending agent. This seems like an easy step, stop-
ping the drug, but it first requires knowing all of the patient's medications and
remembering that diphenylhydantoin can cause hepatitis. Drugs must be considered
as a potential cause in every case of acute hepatic failure.
Many other drugs (e.g., INH, Halothane) can cause acute hepatic failure from a
"hypersensitivity hepatitis." Luckily, these reactions are rare in the younger age
group. For example, halothane hepatitis is extremely rare below age of 11 but in-
creases in incidence above that age [31].
Indeterminate Group Some drugs provoke reactions which are not clearly toxic
or hypersensitive and which progress to hepatic failure. Examples of this group in-
clude aspirin and valproic acid. As a rule, the aspirin lesion occurs only in patients
with lupus or rheumatoid arthritis who are taking maximal therapeutic doses of
aspirin [38]. The hepatitis in these patients is of variable severity but may cause
death. Liver biopsy in such individuals has been reported to show typical
eosinophilic intracellular inclusions but this diagnostic clue is rarely detected. The
new anti-epileptic agent, valproic acid, produces an indolent liver lesion which may
progress to hepatic failure [39]. The liver biopsy findings in these patients are
reported to be typical, and are remarkably mild for the degree of hepatic failure.
This agent is a short-chain fatty acid. The mechanism by which it is toxic is, as yet,
unknown.
The intent in this section has been to provide an overview ofdrug-induced hepatic
reactions, along with a working hypothesis for understanding their pathogenesis.
The examples provided are only a few of the many possible offenders. The point to
remember is that any drug is a possible cause of acute hepatic failure. The clinician
should maintain a high index of suspicion that drugs may injure the liver.
Metabolic/Genetic
Several of the inherited metabolic diseases may terminate with acute hepatic
failure superimposed upon chronic liver disease which may have escaped detection.
With this group are conditions unique to infancy or childhood (Table 6).
Tyrosinemia [40,41] This rare disorder may present acutely within the first four
months of life with hepatic failure and failure to thrive associated with a Fanconi-
like syndrome and rickets. The course is progressively downhill. No effective therapy
is known, although a diet deficient in tyrosine and phenylalanine may prolong life.
The diagnosis is confirmed by amino acid screening of the plasma, which shows a
marked increase in tyrosine levels. Both prematurity and any form ofhepatic failure
in infants may result in alterations in the blood amino acid profile, often with an in-
crease in tyrosine levels. These modest, transient, and non-specific increases should
not be mistaken for the persistent changes seen in hereditary tyrosinemia.
Galactosemia [44,45] This disease presents early in infancy with hepatomegaly
and failure to thrive in infants ingesting lactose-containing formulas. If the correct
diagnosis is not made, the infant goes on to die in acute hepatic failure.
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TABLE 6
Metabolic Diseases Which May Present as "Acute Hepatic Failure"
Common Name Age at Presentation Pathogenic Defect Best Diagnostic Tests
Tyrosinemia [40,41]
(acute form)
Galactosemia [44,451
Fructose
intolerance [46,47]
Alpha-l-antitrypsin
deficiency [48, 49]
Wilson's
disease [50-52]
Infancy
Infancy
Within weeks of
adding fructose
to diet
Infancy
6-50 years
Not yet identified
Galactose-1-phosphate
uridyl transferase
deficiency
Fructose-1-phosphate
aldolase deficiency
Fructose-1,6-
diphosphatase
deficiency
Unknown, a-i-anti-
trypsin accumulates
in liver, is diminished
in serum
Unknown; hepatic
excretion of copper
into bile is impaired
Urine and plasma amino acid
profiles, R/O fructose
intolerance [42], R/O
"neonatal hepatitis" [43]
Urine + for reducing
substances during milk
ingestion, assay of
galactose-l-phosphate
uridyl transferase in red
cells
IV fructose loading test,
assay of fructose-l-
phosplhate aldolase in liver
Glucagon stimulation test,
assay of fructose-1,6-
diphosphatase in liver
Quantitative oa-antitrypsin
level testing, pheniotype
(Pi ZZ homozygotes
associated with disease)
Slit lamp exam for Kayser-
Fleischer Rings; homozy-
gotes usually demonstrate
these abnormalities: Serum
ceruloplasmin <20 mg/dl
24 hour, Urine copper
> 100 ytg, Hepatic copper
>500 ug/g
Fructose Intolerance [42,46,47] This disease presents within days ofweaning the
infant or starting dietary fructose supplements. If this occurs in early infancy, the
patient goes on to develop vomiting, hepatomegaly, failure to thrive, and, ultimately,
death in hepatic failure.
Alpha-l-Antitrypsin Deficiency [48,49] This inherited disease is probably the
single most common cause of liver disease in infancy and should be ruled out in
every child with liver disease. The spectrum of hepatic dysfunction in patients with
this illness is broad, ranging from normal or asymptomatic elevations in the SGOT
all the way to fulminant hepatic failure. Patients in the latter group usually have
some evidence ofpre-existing liver disease, such as failure to thrive or splenomegaly.
The diagnosis may be suspected in patients with low alpha 1-globulin levels on pro-
tein electrophoresis, although this is very non-specific; in order to rule out this
diagnosis, the alpha-l-antitrypsin level should be quantitated. If the level is low
(i.e., < 200 mg/dl), the patient's alpha-l-antitrypsin should be phenotyped. Pa-
tients homozygous for the Pi Z allele are at risk for liver disease. Some studies sug-
gest that even heterozygotes (i.e., Pi MZ or SZ) have an increased risk of liver
disease, at least as adults. For all practical purposes, however, severe neonatal
hepatic dysfunction occurs only in Pi ZZ individuals.
Liver biopsy may be suggestive ofthe diagnosis ofalpha-l-antitrypsin deficiency.
The periportal hepatocytes contain bead-like inclusions which may be inconspicuous
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on routine stains but which are bright cherry red on PAS-digested stain (Fig. 4). The
hepatocytes are also positive on immunofluorescent staining for alpha-1-antitrypsin.
Regardless of these biopsy findings, the diagnosis should be confirmed wth
phenotyping.
There exists no known therapy for this disease. Many patients with mild hepatitis
show resolution. If the disease is fulminant, the prognosis is grim, despite maximal
supportive care.
Wilson's Disease [51,52] This is an inherited disease of copper metabolism. The
exact defect remains undefined, but may be an inability to excrete copper into bile,
its normal excretory route [50]. The result is a build-up ofcopper in various organs,
specifically liver (with a chronic active hepatitis progressive to post-necrotic cir-
rhosis), eye (Kayser-Fleischer rings), brain, and kidney. This disease has myriad
forms of initial presentation. One of these can mimic fulminant hepatitis. Usually
this occurs in patients who have either a previous history or signs of chronic liver
disease. Several clues should suggest Wilson's disease. Hemolytic anemia,
presumably induced by sudden release of copper, is one of these; a defect in renal
tubular function (with hypouricemia) is another. Wilson's disease is a type of
"storage" disease and does not occur in the very young. The usual lower age range is
six years, although we have encountered a patient with jaundice at age two. The
acute presentation certainly occurs in adolescence and Wilson's disease, as one ofthe
few treatable liver diseases, should be ruled out in any child, adolescent, or young
adult with acute hepatic failure.
Proving or disproving this diagnosis is difficult, because the primary defect re-
mains undefined [52]. The single best test is determination ofhepatic copper concen-
tration, but this is usually not possible in someone with the coagulopathy of acute
hepatic failure. The ceruloplasmin level should be determined in all patients with
acute hepatic failure. Ceruloplasmin is decreased, usually as low as 10 mg/dl, in
Wilson's disease, but this protein is an alpha 2 globulin and can increase into the
normal range during acute "hepatitic" flare in Wilson's disease (we have seen values
up to 28 mg/dl). Conversely, in patients with hepatic failure of any etiology, the
ceruloplasmin may decrease (as low as 20 mg/dl) along with the decrease in other
proteins. The urine copper excretion is helpful, provided that the collection is done
in a copper-free vessel. Elevated levels imply long-term excessive copper accumula-
* ' ~~~~~~~~~~~~~~~~~FIG. 4. Theliverina-1-
antitrypsin deficiency: The
A. Af ~~~~~~~~~~~~~~~~PAS diastase digested stain
shows typical rose-colored
bead-like inclusions in the
periportal hepatocytes.
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tion (this occurs in any chronic cholestatic state, as well as in Wilson's). Finally, slit
lap examination of the eye by an ophthalmologist is crucial to rule out the presence
of Kayser-Fleischer rings. Although liver disease can occur in the absence of KF
rings, this is unusual.
The treatment of Wilson's disease is copper chelation, usually with D-penicilla-
mine. Patients who present with acute hepatic failure are often beyond salvage,
however.
Circulatory
Major disruption in the hepatic circulation can result in acute hepatic necrosis,
although this is rarely associated with true hepatic failure. Circulatory failure with
severe hypotension, as in hemorrhagic shock, septic shock, or cardiac arrhythmias,
can result in massive hepatic necrosis, with very high (> 10,000 units) SGOTvalues,
and occasionally transient hepatic dysfunction (short-lived coagulopathy, low-level
elevation of bilirubin). This diagnosis will be suggested by the history and by the
SGOT level. Similarly, impedence ofhepatic outflow, when severe, results in hepatic
failure, although this is usually chronic and invariably associated with ascites and
hepatomegaly. The diagnostic possibilities include Budd-Chiari syndrome, hepatic
veno-occlusive disease associated with radiation ofthe liver and radiomimetic drugs,
and long-standing right-sided congestive heart failure.
MANAGEMENT OF ACUTE HEPATIC FAILURE
Diagnosing the correct cause of acute hepatic failure is important especially as
some forms are iatrogenic and others have specific therapies. But after all diagnostic
maneuvers have been exhausted, a large residue of cases of unknown etiology will
persist. The clinician should remember that, for the most part, the management of
all forms of acute hepatic failure, regardless ofetiology, is the same: support the pa-
tient until the liver regenerates (Table 7).
This support should be the most maximal, the most anticipatory, that the inten-
sive care unit can provide. The liver always has potential for regeneration, so the
physician can never "give up" on the patient with acute hepatic failure. The best sup-
portive care is provided by clinicians who are thoroughly versed in the complications
of acute hepatic failure and who thereby anticipate them (Table 8).
"Complications" ofthe Acute Hepatic Failure
Hepatic Coma [53] By definition, hepatic coma is present in all cases of acute
hepatic failure. The initial stage of coma may be agitation or a change in person-
ality. Treating this stage with sedatives will result in deepening coma, and narcotics
and other CNS depressants must be avoided in acute hepatic failure. Other
precipitants of hepatic coma (see below) include infection, hemorrhage into the GI
tract, hypokalemia, azotemia, rapid shifts in intravascular volume, and excessive
protein ingestion. Each of these precipitants should be looked for in a patient with
coma and corrected ifpossible. Therapy itselfis aimed at lowering blood ammonia,
which may not be the "cause" ofhepatic coma, but which serves as a useful index of
it. This is done by cleansing the bowel with cathartics or enemas and by keeping
bowel function good, two to three stools per day. This rate of catharisis can be
achieved with lactulose, which also changes the gut flora and diminishes production
of ammonia in the colon. The initial dose is 1 cc/kg given by mouth and repeated
every six to eight hours, titrating to a daily stool count of two to three. Diarrhea,
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Guidelines to the Management of Acute Hepatic Failure
General Intensive Care Unit
Monitor I and 0, vital signs, weight, stool guaiacs, electrolytes in urine aild blood
Intubate early for control of airway
Central venous pressure or Swan-Ganz catheter for measuring central pressure if
indicated
Intake Restrict sodium both IV and PO as required
Replace volume as needed with albumin or fresh frozen plasma
Restrict protein as required
Medications No narcotics or sedatives
For coma: Lactulose 1.0 cc/kg q 6 hours as starting dose, titrate to 2-3 stools/day
or neomycin 25 mg/kg q 8 hours as starting dose + a cathartic for 2-3 stools/day
For ascites and edema: Best therapy is salt restriction and no medication
During recovery for chronic ascites: Spironolactone (dose 1-2 mg/kg/day); increase
at 3-5 day intervals
Nutrition Use the oral route if possible
High carbohydrate intake
Give as much protein as tolerated
Of questionable value as protein supplement = special amino acid mixtures
with its attendant hypokalemia, is to be avoided. Lactulose may also be ad-
ministered as a high-retention enema (50:50 mixture of tap water and lactulose).
Neomycin, the poorly absorbed antibiotic, also changes gut flora and diminishes
colonic ammonia production. It can be used as an alternative to lactulose (some pa-
tients develop nausea, cramps, and abdominal bloating on lactulose) but must be
used in conjunction with a cathartic, such as magnesium citrate or milk ofmagnesia.
Protein metabolism (and catabolism) is important in hepatic coma. Protein intake
should be restricted and added back slowly. Protein is crucial to hepatic regenera-
tion, however, so starvation is to be avoided. Protein intake should be titrated
against clinical signs ofhepatic coma and blood ammonia levels. The patient should
receive as much protein as he can tolerate. Protein ingestion plus lactulose is
preferable to no protein ingestion and no lactulose.
TABLE 8
"Complications" to Anticipate in Acute Hepatic Failure
Hepatic coma
Coagulopathy
Ascites and edema
Electrolyte imbalance
Hypoglycemia
Infection: Spontaneous bacterial peritonitis, pneumonia
Renal failure
Cerebral edema
Pancreatitis
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Special amino acid mixtures designed to reverse the amino acid profile in chronic
encephalopathy have been reported to reverse chronic coma. When given either in-
travenously or by mouth, these have not been shown to be effective in acute hepatic
failure and their use in many situations has been questioned. Nevertheless, the mix-
ture is commercially available (as "Hepatic-Aid") and may have a place in the long-
term management of hepatic coma. It should be reserved for patients who are
protein-intolerant. It may be useful as a protein supplement in chronically
encephalopathic patients who are protein-malnourished.
Coagulopathy An elevation in the prothrombin time is present by definition in
acute hepatic failure. All patients should be given a trial of parenteral (not oral)
aquamephyton, usually in a dose in children of 1 mg intramuscularly or intrave-
nously repeated daily for three days. Patients with chronic cholestasis, and hypopro-
thrombinemia on the basis of malabsorption of Vitamin K1, will respond promptly,
i.e., within 12 hours. Patients with acute hepatic failure will show little or no change
in the prothrombin time. If they show a marked change, the diagnosis should be
questioned.
Low-grade DIC, with prolonged PT, PTT and TT, lowered fibrinogen and
platelet counts, and presence of fibrin split products, is common in acute hepatic
failure. It requires no specific therapy (i.e., no heparin) unless diffuse bleeding is
present. If this occurs, it should be treated with infusions of fresh frozen plasma,
although it is almost impossible to correct the coagulopathy completely, regardless
of how much fresh frozen plasma is used. Severe thrombocytopenia is rare, but may
be treated with infusions of platelets. Severe DIC is unusual in uncomplicated acute
hepatic failure. When it occurs, it suggests sepsis, which should be ruled out.
Bleeding Gastrointestinal hemorrhage is very common in acute hepatic failure.
It should be guarded against by avoiding large, stiff nasogastric tubes, and by plac-
ing the patient on a specific regimen to decrease gastric acid. Such a regimen in-
cludes antacids and, in most institutions, prophylactic cimetidine, which has been
shown to diminish bleeding in acute hepatic failure [54]. If bleeding occurs, efforts
to correct the coagulopathy with fresh frozen plasma should be made, and the GI
tract emptied of blood with cathartics and enemas as quickly as possible. Persistent
massive bleeding must be evaluated using the traditional tools (arteriography, en-
doscopy). Varices can occur in acute hepatitis and may be the source of bleeding.
Treatment ofvariceal bleeding in the setting of acute hepatic failure is limited to the
use of vasoactive drugs (vasopressin) to decrease portal pressure. The inexperienced
clinician will often contribute to the problem by over-transfusing the patient,
thereby raising his intravascular volume and the pressure in his varices. A
hematocrit of 30 to 35 is expected in acute hepatic failure and should not be ex-
ceeded. Management of this problem is aided by an accurate measure of central
pressure, using either a CVP line or a Swan-Ganz catheter. Surgery carries a high
risk in the patient with acute hepatic failure and should be avoided. Varices may be
transient and shunt surgery is unwarranted in this setting.
In the face of severecoagulopathy, bleeding at sites other than thegastrointestinal
tract may also occur. Intracranial hemorrhage is a rare but dreaded complication
and should be considered in anypatient with acute hepatic failure who has an abrupt
change in level of consciousness.
Ascites This is a common complication of acute hepatic failure and is much
more difficult to treat, once it has occurred, than it is to prevent. Sodium retention is
to be expected in this setting. The urine sodium excretion reflects this, and in pa-
tients who are euvolemic (as indicated by normal heart rate, blood pressure, and
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urine sodium is often inappropriately low. In this setting, sodium intake should be
restricted before the onset of ascites and edema. Many of these patients will be
moderately hyponatremic (125-135 mEq/L) as a reflection ofhemodilution. Despite
this, usually they will require no intravenous salt and will still maintain normal
serum sodium concentrations. Once edema and ascites occur, thereby documenting
total body sodium excess, no further sodium should be administered. Salt restriction
extends to oral intake also, and these patients should be on a no-salt-added diet ini-
tially, with more strict salt restriction if the urine sodium is low. In the patient with
acute hepatic failure, if repletion of the intravascular volume is required, this is best
achieved using fluids with high oncotic pressure such as albumin. Most hospital
pharmacies now dispense salt-poor albumin only, with a sodium content of 0.5
mEq/g protein. This is much less sodium than is present in the next best choice for
intravenous replacement, namely fresh frozen plasma, with a sodium content of 2.8
mEq/g protein.
Once ascites has accumulated, the clinician should be slow to treat it in the setting
of acute hepatic failure, as almost any treatment will worsen hepatic coma.
Specifically, brisk diuresis, with abrupt shifts in intravascular volume and
hypokalemia, will almost invariably precipitate coma. Ascites alone is not
dangerous, except as a potential source for infection, and should probably only be
treated, in the setting of acute hepatic failure, if respiratory embarrassment occurs.
In this setting, the best management is ginger paracentesis of small volumes, follow-
ing carefully the central pressure and replacing volume as required with albumin.
During recovery from acute hepatic failure, ascites may require therapy if salt
restriction alone does not suffice. The single best diuretic is spironolactone, which
works slowly and prevents hypokalemia. Even small doses of this drug in the acutely
ill patient may result in azotemia and the "hepato-renal" syndrome, however, so it
must be monitored closely. Therapy should be begun with low doses, 1-2
mg/kg/day. If, after four days, the BUN and potassium are stable and the patient
has not lost weight, then the dose should be doubled and the tests repeated. This
schedule of slow increases in dosage may be followed until a gentle diuresis is
achieved. The urine sodium value is useful to demonstrate the dose which provides a
natriuresis. Spironolactone is a long-acting drug, and it should be stopped, not de-
creased, if azotemia is noted. When the ascites has diminished, the drug should be
tapered off as promply as is feasible.
Electrolyte Imbalance Hypokalemia is common in acute hepatic failure and
should be avoided because it causes an increase in renal ammonia production [55].
Potassium supplements should be given to bring the level to 4.0 mEq/L or greater.
Patients on spironolactone may become hyperkalemic and should not receive
potassium on any regular basis.
Hyponatremia is also common and probably reflects hemodilution in response to
the hypoalbuminenemia of acute hepatic failure. Values of greater than 125 mEq/L
require no specific therapy. Below the level, free water restriction should be im-
plemented. Water restriction is not necessary in treating acute hepatic failure except
in the setting of hyponatremia. Giving saline-containing solutions will only increase
the body's salt overload and aggravate edema and ascites.
Alkalosis is common in hepatic coma, presumably resulting from central
hyperventilation. Usually these patients have pH values about 7.45, pCO2 values in
the range of 20-30 mmHg, and high bicarbonate values. The central hyperventila-
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tion is a protective mechanism which decreases cerebral edema and should not be
circumvented by adding dead space to the respirator or by infusing acidifying solu-
tions.
Hypoglycemia This is a common complication of any acute hepatic injury.
Blood glucose values should be obtained frequently, perhaps using frequent dex-
trostick determinations if indicated. Hypoglycemia may mimic hepatic coma. Some
patients will require frequent bolus infusions of concentrated glucose, along with
maintenance 10 percent dextrose infusions.
Infection Sepsis is a common problem in any acutely ill, hospitalized patient and
is frequently the precipitating cause of hepatic coma in acute hepatic failure. In pa-
tients with liver failure, the usual signs ofsepsis, such as fever and leucocytosis, may
be blunted or absent. Sepsis should be ruled out in any patient with acute hepatic
failure who worsens suddenly, particularly if hepatic coma or the hepato-renal syn-
drome develops.
In patients with ascites, spontaneous bacterial peritonitis is common but may be
quite inapparent, without obvious ileus or abdominal tenderness [56]. All patients
with ascites who become febrile, hypotensive, oliguric, or comatose should be
evaluated for spontaneous bacterial peritonitis. A paracentesis is performed, usually
in the linea alba one-third ofthe way below the umbilicus over an empty bladder, us-
ing a small-gauge needle, and a small volume (30 cc) of fluid removed. The fluid is
sent for both aerobic and anaerobic cultures, cell count and differential, protein
determination, and other studies, such as amylase. If the differential cell count con-
tains more than 500 polymorphonucleocytes/ml, then peritonitis should be assumed
to be present, and it should be treated vigorously while results of both blood and
peritoneal cultures are awaited.
The other major source of infection in patients with hepatic coma is the lungs.
This can be minimized by good supportive care, including early intubation for con-
trol of the airway and good pulmonary toilet as well as postural drainage.
Antibiotic use in the jaundiced patient with acute hepatic failure is not without
risk. Such patients seem to be particularly susceptible to the nephrotoxic effects of
aminoglycoside drugs such as gentamicin, despite maintenance of normal blood
levels.
Renal Failure This dreaded complication of acute hepatic failure has been
dubbed the "hepato-renal syndrome" and, when fully established, is almost in-
variably fatal [57,58]. By definition, this is an oliguric form of renal failure and is
characterized by a urine sodium concentration ofless than 10 mEq/L in a euvolemic
patient. The cause ofthis syndrome is not known but is hotly debated. Functionally,
patients with acute hepatic failure behave as if they have depletion of the in-
travascular volume, rendering them particularly sensitive to any further decrease,
such as that associated with septic shock, diuresis, or GI hemorrhage. Any of these
events can push these patients over into progressive renal failure. The kidney in such
patients is normal histologically and can function normally when transplanted into
another patient.
The best treatment for this syndrome is anticipation and prevention. Careful
watch ofthe urine output on an every two- to four-hour basis must be maintained. If
oliguria occurs, the central filling pressure must be promptly assessed by CVP or
Swan-Ganz line. If the pressure is low, volume must be replenished promptly with
high oncotic fluids (e.g., albumin, FFP). Time is of the essence in this setting, and
complete renal shutdown may occur within 12-24 hours of the precipitating event.
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Ifcomplete renal failure occurs, then the patient must be maintained long enough
to allow hepatic regeneration. This can be achieved using either hemo or peritoneal
dialysis. Either is clearly a last-ditch effort in the patient with acute hepatic failure.
Cerebral Edema Studies have shown that this is a common cause of death in
acute hepatic failure [59]. Many pediatric intensive care units have gained
sophistication in managing this problem in patients with Reye's syndrome. In-
tracranial or intracerebral monitoring is usually not part ofthe care ofpatients with
acute hepatic failure but may be, provided it is not contraindicated by severe
coagulopathy. Cerebral edema should not be precipitated by artificially raising the
pCO2 or by excessively volume-loading the patient.
Pancreatitis Acute pancreatitis occurs frequently in acute hepatic failure [60].
Its cause is unknown. This complication should be suspected in any patient with pro-
longed vomiting, ileus, or bloating, although it may be clinically inapparent as well.
Serum amylase and lipase determinations should be done frequently if this com-
plication is suspected. The treatment is identical to that ofacute pancreatitis in other
settings, specifically gut rest. It may be necessary to support the patient with
parenteral nutrition while the pancreatitis resolves.
Miscellaneous Complications The respiratory distress syndrome may accom-
pany any acute major illness and is especially common as a complication of acute
pancreatitis. Good respiratory toilet, early intubation, and monitoring of arterial
blood gases should be part of the management of all patients with acute hepatic
failure. Wide fluctuation in body temperature may occur in acute hepatic failure
presumably because of a failure in central regulation. Either profound hypo- or
hyperthermia is an ominous prognostic sign in acute hepatic failure.
Treatmentfor the Liver
The actual mechanism by which most diseases cause hepatic injury is unknown.
As a result, only in a minority of cases of acute hepatic failure is specific therapy
available to stop or correct the hepatocellular destruction. Specific therapy depends,
of course, on identifying the causative agent.
Stopping the Injury
Drugs The mechanism by which acetaminophen injures the liver has been well
established-namely, one of its metabolites is detoxified in the liver by conjugation
with the sulfhydryl-containing compound glutathione. When an overdose is in-
gested, hepatic glutathione stores are rapidly depleted, and the toxic metabolite
becomes free to covalently bind to structural elements in the hepatocyte, thereby
causing injury. Therapy for acetaminophen poisoning is directed at replenishing
hepatic glutathione stores. This is most easily accomplished by giving Mucomyst
(n-acetyl cysteine). But this antidote must be given before the covalent binding oc-
curs in order to prevent the injury-it is ineffective once necrosis occurs. The cur-
rently recommended regimen is as follows [33]:
1. Gastric aspiration and lavage
2. Acetylcysteine by mouth: 140 mg/kg as a loading dose, 70 mg/kg every
four hours for a total of 17 doses
If the patient vomits persistently, then the acetylcysteine should be given by
duodenal intubation.
Remember, in acetaminophen poisoning the injury is not immediate, but peaks
three days after the ingestion. The antidote must be given as soon as possible after
ingestion in order to prevent injury. Serial blood levels of acetaminophen obtained
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early in the course can be used to calculate the plasma half-life, which correlates well
with the degree of injury. As a rule, however, all patients who have ingested over-
doses of acetaminophen should be treated early, as once the degree of liver damage
becomes evident, it is too late.
If the cause of acute hepatic failure is a prescribed drug (e.g., diphenylhydantoin),
the drug must be stopped. Surprisingly often the physician forgets to establish what
medications the patient is taking or is unaware that the medication can cause liver
disease. In general, all medications should be stopped in patients with acute hepatic
failure. Also surprisingly, often the damage will progress and liver failure worsen,
despite stopping the offending agent.
Metabolic Several of the genetic causes of acute hepatic failure can be treated
by removing the substance whose metabolism is blocked. Specifically, the treatment
for galactosemia or hereditary fructose intolerance is to remove the offending sugar
from the diet. When Wilson's disease presents as acute hepatic failure, most clini-
cians will begin copper chelation with D-penacillamine, despite the fact that this
therapy is ineffective in the pre-terminal patient, as a rule.
Steroids Corticosteroid therapy was advocated for years for the treatment of
acute hepatic failure of viral or unknown etiology. This therapy is very effective in
certain forms of chronic active hepatitis, but has been shown to be of no value in the
treatment of fulminant hepatitis [61]. Some would still recommend the use of
steroids in drug-induced fulminant hepatitis, although no data exist to suggest any
benefit in this setting.
Other Therapies: In theFuture Specific measures, such as interferon or anti-
viral agents, have been tested in limited situations already and, although not yet
suitable for clinical use, may be successful in treating fulminant viral hepatitis. In
the Past Outmoded therapies which have been discarded, for the most part, in-
clude attempts to remove unknown poisons using exchange transfusion, cross-
circulation with another primate, dialysis, or hemoperfusion using a variety of ex-
change columns. A multicenter trial demonstrated that hepatitis B hyperimmune
globulin was ineffective in the treatment of acute hepatitis B.
Stimulating Regeneration If we are usually unable to shut off the injury to the
liver, perhaps we could be more successful in turning on regeneration of new,
healthy liver. This organ is, after all, one of the few which can regenerate normal
tissue. The field of stimulating hepatic regeneration remains in its infancy, however,
as we know relatively little about the modulations of normal hepatic growth. Certain
facts are known and will allow us to speculate about hepatic regeneration and its
control [62].
Experiments in both rats and dogs have demonstrated a "hepatotrophic" effect of
portal blood, as contrasted with blood originating in either the arterial or systemic
venous systems [63]. Regeneration of the liver is enhanced in resected lobes receiving
portal blood [64]. These observations suggest the existence in this blood of
substances which enhance regeneration, so-called "portal vein goodies," which may,
perhaps, be insulin and/or glucagon. Both have been studied as possible stimulators
of hepatic regeneration. In experimental fulminant hepatitis, infused insulin and
glucagon have been demonstrated to promote hepatic recovery [65]. In addition,
some substance within the regenerating liver seems to stimulate regeneration. This
material, so-called hepatic regeneration stimulator substance, is also present in the
livers of weaning rats and enhances regeneration when injected into animals which
have undergone partial hepatectomy [66].
Clearly, amino acid building blocks are also required to repair liver damage. But
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patients with acute hepatic failure have encephalopathy and protein intolerance.
Given this background, it is clear that nutrition may play an important role in the
management of patients with acute hepatic failure. Practically, the clinician should
keep the blood sugar level high. Carbohydrates administered by mouth (thus
reaching the liver via the portal vein) are the best stimulants to endogenous insulin
and glucagon. Ifthe PO route cannot be used because the patient refuses to eat, can-
not tolerate a nasogastric tube, or because ofpancreatitis and ileus, high concentra-
tions ofglucose should be administered via a central intravenous line, along with in-
sulin if necessary. In addition, the patient with acute hepatic failure should be given
as much protein as he can tolerate, again preferably by mouth. If standard food or
protein mixtures exacerbate hyperammonemia, then special amino acid mixtures
may be tried, although without proofof benefit. Again, ifthe oral route is contrain-
dicated for one or another reason, then intravenous amino acids may be given, as
long as care is taken to avoid worsening hepatic coma.
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